NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within NVIDIA's AI portfolio, especially in the fledgling AI biotech sector. As a ...

We recently published a list of the Top 10 AI Stocks Buzzing on Latest News. In this article, we are going to take a look at ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) soared 40 percent week-on-week, with the company also experiencing a ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $8.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...